Semaglutide
InjectionWeight Loss
InjectionWeight LossIn stock
Tirzepatide injection
A once-weekly dual GIP and GLP-1 receptor agonist that gives weight-loss programs a higher-ceiling tirzepatide option — with the intake, billing, and refill infrastructure to launch and scale it.
Dose
Once weekly
Avg. loss · 72 wks
−20.9%
Format
Weekly subcutaneous injection
Dose range
2.5 mg to 15 mg once weekly
Rx required
Yes — licensed provider review
Program fit
High-intent weight-loss protocol
About the medication
Dual-incretin weight loss therapy with a higher efficacy ceiling
Tirzepatide activates both GIP and GLP-1 receptors. In the phase 3 SURMOUNT-1 trial, adults with obesity or overweight without diabetes lost an average of 20.9% of body weight at 72 weeks on the 15 mg dose, compared with 3.1% with placebo.
- Targets both GIP and GLP-1 pathways involved in appetite, satiety, and energy balance
- Designed as a once-weekly injection with gradual dose escalation
- In SURMOUNT-1, 91% of participants on 15 mg achieved at least 5% weight loss
- Strong fit for clinics that want a premium GLP-1 program with higher weight-loss expectations
Mechanism
Dual GIP and GLP-1 receptor agonist
Delivery
Subcutaneous once-weekly injection (abdomen, thigh, arm)
Onset
Appetite changes during escalation; weight loss builds over 24–72 weeks
Oversight
Every order routed through a licensed provider review
Expected results
Higher-end weight-loss outcomes for weekly injection programs
Based on published SURMOUNT-1 outcomes at 72 weeks. Real-world results depend on tolerated maintenance dose, titration adherence, lifestyle changes, and individual response.
20.9%
Avg. total body weight loss
at 72 weeks, 15 mg dose
91%
Patients losing ≥5% weight
at week 72 on 15 mg
57%
Patients losing ≥20% weight
at week 72 on 15 mg
Mean change in body weight
% change from baseline · weeks 0–68
Tirzepatide 15 mgPlacebo
At week 68
−20.9%
Tirzepatide 15 mg
At week 68
−3.1%
Placebo
Net difference
−17.8 pts
vs. placebo
Illustrative — based on published SURMOUNT-1 outcomes. Not a clinical guarantee. Provider-directed protocols, tolerated dose, and pharmacy workflow may vary.
Dosing protocol
Standard titration schedule
Zepbound labeling starts at 2.5 mg weekly for 4 weeks, then increases in 2.5 mg steps after at least 4 weeks on the current dose. Your providers can hold, slow, or stop escalation based on tolerability.
- 1Weeks 1–42.5 mgInitiation dose
- 2Weeks 5–85 mgFirst escalation step
- 3Weeks 9–127.5 mgOptional step-up if tolerated
- 4Weeks 13–1610 mgCommon mid-program maintenance level
- 5Weeks 17–2012.5 mgHigher-dose escalation step
- 6Week 21+15 mgMaximum labeled maintenance dose
The Turbopills stack for this program
Everything you need to run a tirzepatide program
Pick the pieces you want. Use your own brand, your own providers, your own price — powered by a single, compliant backend.
Product website & ad landing pages
Turbopills AI Studio — ad images & videos
BetaProvider review & e-Rx
Pharmacy order routing
Refills & auto-ship
Experiments & A/B tests
BetaReady to launch
Ship a tirzepatide program in weeks — not quarters.
The platform ships the intake flow, billing, subscriptions, refill workflows, and the operator console your team works in. Bring your licensed providers and pharmacy partners; we wire everything into one backend so you launch in weeks, not quarters.
Marketing and educational content only. Clinical details on this page are summarized from publicly available sources to help operators scope a program — they are not medical advice, dosing instructions, or a recommendation for any individual patient. Real patient care requires a licensed provider and a compliant pharmacy partner; Turbopills provides the software that helps brands run the program around them.
Related
